Anteris Technologies Global (NASDAQ:AVR) Stock Rating Raised to Hold at Barclays

Barclays upgraded shares of Anteris Technologies Global (NASDAQ:AVR) to a hold rating in a research note published on Wednesday morning,Zacks reports.

A number of other equities research analysts have also commented on AVR. Cantor Fitzgerald restated an “overweight” rating and set a $15.00 price objective on shares of Anteris Technologies Global in a research report on Friday, August 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anteris Technologies Global in a report on Wednesday, August 26th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $14.00.

Anteris Technologies Global Stock Down 3.3%

AVR opened at $6.82 on Wednesday. The stock has a fifty day moving average of $8.44 and a 200-day moving average of $8.02. The firm has a market capitalization of $664.68 million, a P/E ratio of -3.50 and a beta of 1.87. Anteris Technologies Global has a 12-month low of $3.30 and a 12-month high of $11.06.

Anteris Technologies Global (NASDAQ:AVR) last issued its earnings results on Tuesday, August 11th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.09). The business had revenue of $1.01 million during the quarter, compared to analyst estimates of $1.50 million. Anteris Technologies Global had a negative return on equity of 77.69% and a negative net margin of 4,619.27%.During the same period last year, the business earned ($0.58) EPS. On average, analysts expect that Anteris Technologies Global will post -1.21 earnings per share for the current fiscal year.

Insider Activity at Anteris Technologies Global

In related news, major shareholder L1 Capital Pty Ltd purchased 648,455 shares of the stock in a transaction dated Monday, October 5th. The shares were acquired at an average cost of $7.51 per share, for a total transaction of $4,869,897.05. Following the acquisition, the insider directly owned 12,778,380 shares in the company, valued at approximately $95,965,633.80. The trade was a 5.35% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders have acquired 1,282,035 shares of company stock worth $9,736,563 and have sold 3,008,459 shares worth $25,243,576. 4.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Anteris Technologies Global

Hedge funds and other institutional investors have recently modified their holdings of the company. Nantahala Capital Management LLC acquired a new stake in Anteris Technologies Global during the second quarter valued at $33,325,850. One68 Global Capital LLC acquired a new position in Anteris Technologies Global in the 2nd quarter worth about $128,000. Bank of America Corp DE purchased a new stake in shares of Anteris Technologies Global during the 2nd quarter worth about $1,907,000. AWM Investment Company Inc. purchased a new stake in shares of Anteris Technologies Global during the 2nd quarter worth about $1,133,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Anteris Technologies Global during the 2nd quarter valued at about $30,979,000.

More Anteris Technologies Global News

Here are the key news stories impacting Anteris Technologies Global this week:

• Positive Sentiment: Major shareholder made substantial purchases. L1 Capital Pty Ltd bought 648,455 AVR shares on October 5 at an average of $7.51, worth approximately $4.87 million, increasing its position by 5.35% to 12.78 million shares. The investor also purchased 236,354 shares on October 2 for about $1.84 million. The buying may bolster confidence because a large shareholder is committing additional capital while the stock is trading below recent moving averages. AVR insider buying report
• Neutral Sentiment: Share and incentive records were updated. Anteris reported a slight decrease in CHESS Depositary Interests and the lapse or cessation of several restricted stock unit and option tranches. These changes could affect the share count and potential dilution, but no new operating, clinical, or regulatory catalyst was announced. AVR CDI and equity incentive update
• Negative Sentiment: Financial performance remains weak. Anteris’ latest quarterly loss of $0.30 per share was wider than the $0.21 consensus estimate, while revenue of $1.01 million trailed expectations of $1.50 million. The clinical-stage structural-heart company remains unprofitable, with analysts expecting a full-year loss, factors that continue to weigh on valuation and investor sentiment. AVR earnings and performance report

Anteris Technologies Global Company Profile

Anteris Technologies Global is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company’s lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow.

Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution.

The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States.